Are changes in echocardiographic parameters like volumes, strain, and ventricular-arterial coupling associated with LVEF declines in breast cancer patients treated with doxorubicin and trastuzumab?
Detailed echocardiographic phenotyping, including strain and ventricular-arterial coupling, tracks with LVEF decline and recovery in breast cancer patients undergoing cardiotoxic chemotherapy.
Doxorubicin and trastuzumab resulted in modest, persistent declines in LVEF at 3 years. Changes in volumes, strain, and ventricular-arterial coupling were consistently associated with concurrent and subsequent LVEF declines and recovery across therapies.
Narayan et al. (Fri,) studied this question.